GlassScriptPhysician profile
Surabhi A Khanna
NPI 1124220157
$12,654.76
in general payments reported to CMS, 2019-2025
20 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $7,956 · 2023: $735 · 2024: $2,489 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579 · Consulting Fee: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.08 |
| Consulting Fee | $2,120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,095.02 | 2022-2025 | Ofev, Spevigo |
| Abbvie INC. | $553.50 | 2023-2025 | |
| Amgen INC. | $495.89 | 2023-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $281.45 | 2023-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $235.47 | 2022-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $234.48 | 2023-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $214.55 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $150.15 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.92 | 2023 | Sotyktu |
| Lilly USA, LLC | $78.46 | 2023-2025 | Olumiant, Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $46.13 | 2023-2024 | Saphnelo |
| Pfizer INC. | $44.68 | 2023-2024 | |
| Bioventus LLC | $31.09 | 2023 | Durolane |
| Almatica Pharma LLC | $22.75 | 2025 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $18.81 | 2025 | Uptravi, Opsynvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.01 | 2025 | Actemra |
| Kiniksa Pharmaceuticals International, Plc | $14.40 | 2024 | Arcalyst |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.